Seminars in Nuclear Medicine
Volume 37, Issue 6 , Pages 451-461 , November 2007

Hypoxia Positron Emission Tomography Imaging With 18F-Fluoromisonidazole

  • Sze Ting Lee, MBBS, FRACP
    • ,
  • Andrew M. Scott, MBBS, MD, FRACP, DDU

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Andrew M. Scott, MBBS, MD, FRACP, DDU, Director, Centre for PET & Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Austin Health, 145, Studley Road, Heidelberg, Victoria 3084, Australia.

References 

  1. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol. 2006;82:699–757
  2. Foo SS, Abbott DF, Lawrentschuk N, et al. Functional imaging of intratumoral hypoxia. Mol Imaging Biol. 2004;6:291–305
  3. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996;56:941–943
  4. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509–4515
  5. Hockel M, Schlenger K, Hockel S, et al. Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer. 1998;79:365–369
  6. Sundfor K, Lyng H, Rofstad EK. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer. 1998;78:822–827
  7. Walenta S, Wetterling M, Lehrke M, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 2000;60:916–921
  8. Powis G, Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther. 2004;3:647–654
  9. Kerbel RS. New targets, drugs, and approaches for the treatment of cancer: An overview. Cancer Metastasis Rev. 1998;17:145–147
  10. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999;59:5830–5835
  11. Zagzag D, Friedlander DR, Margolis B, et al. Molecular events implicated in brain tumor angiogenesis and invasion. Pediatr Neurosurg. 2000;33:49–55
  12. Hockel M, Schlenger K, Hockel S, et al. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 1999;59:4525–4528
  13. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer. 2000;36:1649–1660
  14. Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res. 1996;56:5754–5757
  15. Blancher C, Harris AL. The molecular basis of the hypoxia response pathway: Tumour hypoxia as a therapy target. Cancer Metastasis Rev. 1998;17:187–194
  16. Padhani AR, Krohn KA, Lewis JS, et al. Imaging oxygenation of human tumours. Eur Radiol. 2007;17:861–872
  17. Menon C, Fraker DL. Tumor oxygenation status as a prognostic marker. Cancer Lett. 2005;221:225–235
  18. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med. 2001;7:987–989
  19. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62
  20. Wouters BG, Weppler SA, Koritzinsky M, et al. Hypoxia as a target for combined modality treatments. Eur J Cancer. 2002;38:240–257
  21. Padera TP, Stoll BR, Tooredman JB, et al. Pathology: cancer cells compress intratumour vessels. Nature. 2004;427:695
  22. Hall EJ. Radiobiology for the Radiologist. (ed 3). Philadelphia: Lippincott; 1988;
  23. Hockel M, Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266–276
  24. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005;10:86–103
  25. Stone HB, Brown JM, Phillips TL, et al. Oxygen in human tumors: Correlations between methods of measurement and response to therapy (Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland). Radiat Res. 1993;136:422–434
  26. Hicks RJ, Dorow D, Roselt P. PET tracer development–a tale of mice and men. Cancer Imaging. 2006;6:S102–S106
  27. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199–212
  28. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417–428
  29. Rajendran JG, Wilson DC, Conrad EU, et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: Correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 2003;30:695–704
  30. Lawrentschuk N, Poon AM, Foo SS, et al. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int. 2005;96:540–546
  31. Cherk MH, Foo SS, Poon AM, et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-fluoromisonidazole and 18F-FDG PET. J Nucl Med. 2006;47:1921–1926
  32. Brown JM, Workman P. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res. 1980;82:171–190
  33. Grunbaum Z, Freauff SJ, Krohn KA, et al. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. J Nucl Med. 1987;28:68–75
  34. Fukuda K, Taniguchi H, Koh T, et al. Relationships between oxygen and glucose metabolism in human liver tumours: Positron emission tomography using (15)O and (18)F-deoxyglucose. Nucl Med Commun. 2004;25:577–583
  35. Flockhart IR, Large P, Troup D, et al. Pharmacokinetic and metabolic studies of the hypoxic cell radiosensitizer misonidazole. Xenobiotica. 1978;8:97–105
  36. Tochon-Danguy HJ, Sachinidis JI, Chan F, et al. Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO). Nucl Med Biol. 2002;29:191–197
  37. Graham MM, Peterson LM, Link JM, et al. Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. J Nucl Med. 1997;38:1631–1636
  38. Lim JL, Berridge MS. An efficient radiosynthesis of [18F]fluoromisonidazole. Appl Radiat Isot. 1993;44:1085–1091
  39. Davda S, Bezabeh T. Advances in methods for assessing tumor hypoxia in vivo: Implications for treatment planning. Cancer Metastasis Rev. 2006;25:469–480
  40. Gatenby RA, Kessler HB, Rosenblum JS, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1988;14:831–838
  41. Rofstad EK, Sundfor K, Lyng H, et al. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer. 2000;83:354–359
  42. Kallinowski F, Zander R, Hoeckel M, et al. Tumor tissue oxygenation as evaluated by computerized-pO2-histography. Int J Radiat Oncol Biol Phys. 1990;19:953–961
  43. Vaupel P, Schlenger K, Knoop C, et al. Oxygenation of human tumors: Evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res. 1991;51:3316–3322
  44. Shelton ME, Dence CS, Hwang DR, et al. Myocardial kinetics of fluorine-18 misonidazole: A marker of hypoxic myocardium. J Nucl Med. 1989;30:351–358
  45. Cater DB, Silver IA. Quantitative measurements of oxygen tension in normal tissues and in the tumours of patients before and after radiotherapy. Acta Radiol. 1960;53:233–256
  46. Fyles AW, Milosevic M, Wong R, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol. 1998;48:149–156
  47. Kolstad P. Intercapillary distance, oxygen tension and local recurrence in cervix cancer. Scand J Clin Lab Invest Suppl. 1968;106:145–157
  48. Knocke TH, Weitmann HD, Feldmann HJ, et al. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol. 1999;53:99–104
  49. Hockel M, Knoop C, Schlenger K, et al. Intratumoral pO2 histography as predictive assay in advanced cancer of the uterine cervix. Adv Exp Med Biol. 1994;345:445–450
  50. Lyng H, Sundfor K, Rofstad EK. Oxygen tension in human tumours measured with polarographic needle electrodes and its relationship to vascular density, necrosis and hypoxia. Radiother Oncol. 1997;44:163–169
  51. Doll CM, Milosevic M, Pintilie M, et al. Estimating hypoxic status in human tumors: A simulation using Eppendorf oxygen probe data in cervical cancer patients. Int J Radiat Oncol Biol Phys. 2003;55:1239–1246
  52. Hockel M, Schlenger K, Mitze M, et al. Hypoxia and radiation response in human tumors. Semin Radiat Oncol. 1996;6:3–9
  53. Nordsmark M, Loncaster J, Chou SC, et al. Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. Int J Radiat Oncol Biol Phys. 2001;49:581–586
  54. Lartigau E, Randrianarivelo H, Avril MF, et al. Intratumoral oxygen tension in metastatic melanoma. Melanoma Res. 1997;7:400–406
  55. Nordsmark M, Hoyer M, Keller J, et al. The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 1996;35:701–708
  56. Bentzen L, Keiding S, Nordsmark M, et al. Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol. 2003;67:339–344
  57. Brizel DM, Rosner GL, Harrelson J, et al. Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 1994;30:635–642
  58. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997;38:285–289
  59. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 1996;41:31–39
  60. Stadler P, Becker A, Feldmann HJ, et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 1999;44:749–754
  61. Eschwege F, Bourhis J, Girinski T, et al. Predictive assays of radiation response in patients with head and neck squamous cell carcinoma: A review of the Institute Gustave Roussy experience. Int J Radiat Oncol Biol Phys. 1997;39:849–853
  62. Lartigau E, Le Ridant AM, Lambin P, et al. Oxygenation of head and neck tumors. Cancer. 1993;71:2319–2325
  63. Becker A, Hansgen G, Bloching M, et al. Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. Int J Radiat Oncol Biol Phys. 1998;42:35–41
  64. Brizel DM, Dodge RK, Clough RW, et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol. 1999;53:113–117
  65. Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253–260
  66. Gagel B, Reinartz P, Dimartino E, et al. pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2′-deoxyglucose) (An appraisal of radiotherapeutically relevant hypoxia). Strahlenther Onkol. 2004;180:616–622
  67. Zimny M, Gagel B, Dimartino E, et al. FDG—a marker of tumour hypoxia? (A comparison with [(18)F]fluoromisonidazole and pO (2)-polarography in metastatic head and neck cancer). Eur J Nucl Med Mol Imaging. 2006;33:1426–1431
  68. Brown JM, Giaccia AJ. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res. 1998;58:1408–1416
  69. Gatenby RA, Coia LR, Richter MP, et al. Oxygen tension in human tumors: In vivo mapping using CT-guided probes. Radiology. 1985;156:211–214
  70. Rasey JS, Nelson NJ, Chin L, et al. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res. 1990;122:301–308
  71. Valk PE, Mathis CA, Prados MD, et al. Hypoxia in human gliomas: Demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med. 1992;33:2133–2137
  72. Bruehlmeier M, Roelcke U, Schubiger PA, et al. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J Nucl Med. 2004;45:1851–1859
  73. Cher LM, Murone C, Lawrentschuk N, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med. 2006;47:410–418
  74. Rajendran JG, Schwartz DL, O’Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435–5441
  75. Thorwarth D, Eschmann SM, Holzner F, et al. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol. 2006;80:151–156
  76. Hicks RJ, Rischin D, Fisher R, et al. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging. 2005;32:1384–1391
  77. Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19:535–542
  78. Rischin D, Hicks RJ, Fisher R, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol. 2006;24:2098–2104
  79. Gagel B, Reinartz P, Demirel C, et al. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: A feasibility study. BMC Cancer. 2006;6:51
  80. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys. 1995;33:391–398
  81. Read SJ, Hirano T, Abbott DF, et al. Identifying hypoxic tissue after acute ischemic stroke using PET and 18F-fluoromisonidazole. Neurology. 1998;51:1617–1621
  82. Read SJ, Hirano T, Abbott DF, et al. The fate of hypoxic tissue on 18F-fluoromisonidazole positron emission tomography after ischemic stroke. Ann Neurol. 2000;48:228–235
  83. Markus R, Reutens DC, Kazui S, et al. Hypoxic tissue in ischaemic stroke: Persistence and clinical consequences of spontaneous survival. Brain. 2004;127:1427–1436
  84. Markus R, Donnan G, Kazui S, et al. Penumbral topography in human stroke: Methodology and validation of the ‘Penumbragram’. Neuroimage. 2004;21:1252–1259
  85. Markus R, Donnan GA, Kazui S, et al. Statistical parametric mapping of hypoxic tissue identified by [(18)F]fluoromisonidazole and positron emission tomography following acute ischemic stroke. Neuroimage. 2002;16:425–433
  86. Hirano T, Read SJ, Abbott DF, et al. No evidence of hypoxic tissue on 18F-fluoromisonidazole PET after intracerebral hemorrhage. Neurology. 1999;53:2179–2182
  87. Caldwell JH, Revenaugh JR, Martin GV, et al. Comparison of fluorine-18-fluorodeoxyglucose and tritiated fluoromisonidazole uptake during low-flow ischemia. J Nucl Med. 1995;36:1633–1638
  88. Martin GV, Caldwell JH, Graham MM, et al. Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J Nucl Med. 1992;33:2202–2208
  89. Hotchkiss RS, Rust RS, Dence CS, et al. Evaluation of the role of cellular hypoxia in sepsis by the hypoxic marker [18F]fluoromisonidazole. Am J Physiol. 1991;261:R965–R972
  90. Liu RS, Chu LS, Yen SH, et al. Detection of anaerobic odontogenic infections by fluorine-18 fluoromisonidazole. Eur J Nucl Med. 1996;23:1384–1387
  91. Sorger D, Patt M, Kumar P, et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): A comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol. 2003;30:317–326
  92. Piert M, Machulla HJ, Picchio M, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med. 2005;46:106–113
  93. Gronroos T, Bentzen L, Marjamaki P, et al. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:513–520
  94. Solomon B, Binns D, Roselt P, et al. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Mol Cancer Ther. 2005;4:1417–1422
  95. Fujibayashi Y, Taniuchi H, Yonekura Y, et al. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155–1160
  96. O’Donoghue JA, Zanzonico P, Pugachev A, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys. 2005;61:1493–1502
  97. Laforest R, Dehdashti F, Lewis JS, et al. Dosimetry of 60/61/62/64Cu-ATSM: A hypoxia imaging agent for PET. Eur J Nucl Med Mol Imaging. 2005;32:764–770
  98. Lewis JS, McCarthy DW, McCarthy TJ, et al. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med. 1999;40:177–183
  99. Obata A, Yoshimoto M, Kasamatsu S, et al. Intra-tumoral distribution of (64)Cu-ATSM: A comparison study with FDG. Nucl Med Biol. 2003;30:529–534
  100. Yuan H, Schroeder T, Bowsher JE, et al. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med. 2006;47:989–998
  101. Gronroos T, Eskola O, Lehtio K, et al. Pharmacokinetics of [18F]FETNIM: A potential marker for PET. J Nucl Med. 2001;42:1397–1404
  102. Lehtio K, Oikonen V, Gronroos T, et al. Imaging of blood flow and hypoxia in head and neck cancer: Initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET. J Nucl Med. 2001;42:1643–1652
  103. Lehtio K, Oikonen V, Nyman S, et al. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging. 2003;30:101–108
  104. Tolvanen T, Lehtio K, Kulmala J, et al. 18F-Fluoroerythronitroimidazole radiation dosimetry in cancer studies. J Nucl Med. 2002;43:1674–1680
  105. Evans SM, Kachur AV, Shiue CY, et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med. 2000;41:327–336
  106. Kachur AV, Dolbier WR, Evans SM, et al. Synthesis of new hypoxia markers EF1 and [18F]-EF1. Appl Radiat Isot. 1999;51:643–650
  107. Dolbier WR, Li AR, Koch CJ, et al. [18F]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure. Appl Radiat Isot. 2001;54:73–80
  108. Ziemer LS, Evans SM, Kachur AV, et al. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur J Nucl Med Mol Imaging. 2003;30:259–266

PII: S0001-2998(07)00084-0

doi: 10.1053/j.semnuclmed.2007.07.001

Seminars in Nuclear Medicine
Volume 37, Issue 6 , Pages 451-461 , November 2007

Article Tools

* Image Usage & Resolution